Publications and Presentations
Revolutionising Cancer Care for Pancreatic, Gastro-intestinal and Rare Cancers:
Your Support, Their Hope.
Priority Needs Projects
Click here, to download your PDF copy.
WARPNINE Annual Review
Financial Year 2022 -2023
Click here, to download your PDF copy.
The Lancet
Gastroenterology & Hepatology
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study
Published:July 05, 2022 DOI: https://doi.org/10.1016/S2468-1253(22)00167-4
We are delighted to share the findings, recently published in The Lancet, from the first-in-human study by Dr Andrew Dean, Chair of WARPNINE, and colleagues.
Although early phase, this study showed the best ever result ever seen in a pancreatic cancer trial.
This article was published in The Lancet Gastroenterology & Hepatology, Vol 7, Andrew Dean, Sanjeev Gill, Mark McGregor, Vy Broadbridge, Harri A Järveläinen, Timothy Price, Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study, Copyright Elsevier Ltd (2022).